The age-related disease drug developer, which counts Mayo Clinic and WuXi PharmaTech as investors, raised $55m as recently as last month.

Duke spinout Element could generate as much as $30m from the sale, which will enable UCB to boost its research capabilities.

Ola has acquired Times Internet-backed public transportation app developer Ridlr in an all-stock deal reportedly worth almost $50m.

Purdue-born Spensa recently detailed how its live insect phenology model could help farmers predict how insect populations develop.

Samsung-backed nLight Photonics has filed for an initial public offering, aiming to raise approximately $86.3m when it floats on the Nasdaq Global Market.

Aptus Therapeutics-backed Alzheon has set its pricing range at $13 to $15 and could raise almost $86.3m if underwriters take up their option to purchase additional shares.

Unum Therapeutics has listed on the Nasdaq Global Select Market, providing exits to Novo, Sanofi, EMS and Seattle Genetics.

Novartis-backed Homology Medicines priced its shares at $16 and raised $165m when it floated on the Nasdaq Global Select Market.

The corporate has agreed to acquire Mobike, backed by Tencent, for $2.7bn.

Following reports in February, Alibaba has confirmed it will acquire the remaining shares in Ele.me, currently owned by investors such as JD.com, Tencent and Baidu.